By Fineline Cube 
NovaBridge Biosciences (formerly I‑Mab, NASDAQ: IMAB) announced today that its corporate name change is now official. Starting the next trading day, the company’s American Depositary Shares (ADS) will trade under the new ticker NBP (NASDAQ: NBP), replacing the former symbol IMAB.
Rebranding Highlights
- Effective Date – The name change takes effect at the market opening on 30 Oct 2025.
- Investor Communication – All investor relations materials, regulatory filings, and market listings will reflect the new name and ticker.
- Strategic Rationale – The transition underscores the company’s evolving focus on a diversified oncology pipeline and global expansion.
Pipeline Overview
NovaBridge’s differentiated portfolio centers on two lead candidates:
| Candidate | Mechanism | Development Stage | Notes |
|---|---|---|---|
| Givastomig | Bispecific antibody (Claudin‑18.2 × 4‑1BB) | Pre‑clinical/early‑clinical | Potential best‑in‑class bispecific targeting solid‑tumor antigens and costimulatory signals. |
| VIS‑101 | Bifunctional biologic (VEGF‑A + ANG‑2 inhibition) | Phase I/II (partnered with Aosaikang) | Second‑in‑class dual‑target agent aimed at tumor angiogenesis and vascular permeability. |
- Strategic Partnerships – VIS‑101 is co‑developed with Aosaikang, leveraging its expertise in vascular biology.
- Pipeline Differentiation – The combination of bispecific antibody technology and dual‑target biologics positions NovaBridge at the forefront of next‑generation oncology therapeutics.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech